1
|
Russo GI, Musso N, Lo Giudice A, Asmundo MG, Di Mauro M, Bonacci PG, Massimino M, Bivona D, Stefani S, Pricoco E, Ferro M, Camarda M, Cimino S, Morgia G, Caltabiano R, Broggi G. PD-1, PD-L1 and cAMP immunohistochemical expressions are associated with worse oncological outcome in patients with bladder cancer. J Cancer Res Clin Oncol 2022:10.1007/s00432-022-04262-0. [PMID: 35972693 DOI: 10.1007/s00432-022-04262-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2022] [Accepted: 08/02/2022] [Indexed: 11/24/2022]
Abstract
PURPOSE In this study, we aimed to identify prognostic factors of cancer mortality in patients who received radical cystectomy and to identify genomic alterations in a sub-cohort of patients with locally advanced (pT3-4) and/or positive lymph nodes bladder cancer (BC). METHODS We collected 101 BC samples from 2010 to 2018 who previously received radical cystectomy. Immunohistochemical slides were evaluated for PPAR, cAMP, IMP3, Ki67, CDK4, POU5F1, Cyclin E and MDM2, p65, CD3, CD4, CD8, CD20, CD68, CD163, FOXP3, PD-1 and PD-L1 expression. We calculated a prognostic score (PS) based on the positivity to PD-1, PD-L1 and of cAMP (final score ranging from 0 to 3). DNA of each sample have been used for sequencing by NGS in a sub-cohort of 6 patients with locally advanced (pT3-4) and/or positive lymph nodes BC. RESULTS PD-1 + (HR [hazard ratio] 2.59; p = 0.04), PD-L1+ (HR = 6.46; p < 0.01) and cAMP+ (HR 3.04; p = 0.02) were independent predictors of cancer-specific mortality (CSM). Increase of PS (score = 0 as reference) was associated with CSM, 0.81 (p = 0.80), 4.72 (p = 0.01) and 10.51 (p < 0.0) for PS 1, 2 and 3, respectively. ERBB2 was the gene most frequently mutated. CONCLUSION BC exhibited heterogenous protein expression and variable genomic features. Identification of expression of PD-1, PD-L1 and cAMP could help in predicting oncological outcomes.
Collapse
Affiliation(s)
- Giorgio Ivan Russo
- Urology Section, Department of Surgery, University of Catania, 95123, Catania, Italy.
| | - Nicolò Musso
- Department of Biomedical and Biotechnological Sciences (BIOMETEC), University of Catania, 95123, Catania, Italy.,STLab S.R.L., Catania, Italy
| | - Arturo Lo Giudice
- Urology Section, Department of Surgery, University of Catania, 95123, Catania, Italy.,Department of Urology, European Institute of Oncology, IRCCS, Milan, Italy
| | | | - Marina Di Mauro
- Urology Section, Department of Surgery, University of Catania, 95123, Catania, Italy
| | - Paolo G Bonacci
- Department of Biomedical and Biotechnological Sciences (BIOMETEC), University of Catania, 95123, Catania, Italy
| | - Mariacristina Massimino
- Department of Biomedical and Biotechnological Sciences (BIOMETEC), University of Catania, 95123, Catania, Italy
| | - Dalida Bivona
- Department of Biomedical and Biotechnological Sciences (BIOMETEC), University of Catania, 95123, Catania, Italy
| | - Stefania Stefani
- Department of Biomedical and Biotechnological Sciences (BIOMETEC), University of Catania, 95123, Catania, Italy
| | - Elisabetta Pricoco
- Department of Medical and Surgical Sciences and Advanced Technologies "G. F. Ingrassia", Anatomic Pathology, University of Catania, 95123, Catania, Italy
| | - Matteo Ferro
- Department of Urology, European Institute of Oncology, IRCCS, Milan, Italy
| | | | - Sebastiano Cimino
- Urology Section, Department of Surgery, University of Catania, 95123, Catania, Italy
| | - Giuseppe Morgia
- Urology Section, Department of Surgery, University of Catania, 95123, Catania, Italy.,Department of Experimental Oncology, Mediterranean Institute of Oncology (IOM), 95029, Catania, Italy
| | - Rosario Caltabiano
- Department of Medical and Surgical Sciences and Advanced Technologies "G. F. Ingrassia", Anatomic Pathology, University of Catania, 95123, Catania, Italy
| | - Giuseppe Broggi
- Department of Medical and Surgical Sciences and Advanced Technologies "G. F. Ingrassia", Anatomic Pathology, University of Catania, 95123, Catania, Italy
| |
Collapse
|
2
|
Flippot R, Loriot Y. The FGFR3 Story in Bladder Cancer: Another Piece of the Puzzle? Eur Urol 2020; 78:688-689. [PMID: 32855010 DOI: 10.1016/j.eururo.2020.08.016] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2020] [Accepted: 08/13/2020] [Indexed: 11/16/2022]
Affiliation(s)
- Ronan Flippot
- Department of Medical Oncology, INSERM U981, Gustave Roussy, University Paris-Saclay, Villejuif, France
| | - Yohann Loriot
- Department of Medical Oncology, INSERM U981, Gustave Roussy, University Paris-Saclay, Villejuif, France.
| |
Collapse
|